Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 6:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,469 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard Oral Care Clear all
Not yet recruiting Phase 2 Interventional

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

NCT07619365
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Lovastatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 7, 2026, 6:26 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

NCT06106308
View directory record Official record
Conditions
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326
View directory record Official record
Conditions
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Monterey, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

NCT06072482
View directory record Official record
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
Avacopan, Placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
62
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

NCT06904378
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ONT01, Gemcitabine, Nab paclitaxel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Recruiting No phase listed Observational

Clinical and Molecular Features of Oral Premalignancy and Oral Cancer

NCT06550050
View directory record Official record
Conditions
Oral Cancer
Interventions
Radiation
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2066
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Not yet recruiting Phase 4 Interventional

Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery

NCT07600697
View directory record Official record
Conditions
Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative Pain
Interventions
Suzetrigine, Opioid Analgesics (Tramadol or Oxycodone), Scheduled Acetaminophen and Ibuprofen
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

NCT00670046
View directory record Official record
Conditions
Prostate Cancer
Interventions
valproic acid, standard of care follow-up
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 7, 2026, 6:26 PM EDT
Completed No phase listed Observational Results available

Pilot Study Assessing Oxidative Stress in Children

NCT01052207
View directory record Official record
Conditions
Adrenal Insufficiency, Critical Illness
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Day to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 7, 2026, 6:26 PM EDT
Not yet recruiting Phase 2 Interventional

Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

NCT07715734
View directory record Official record
Conditions
Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney Transplant
Interventions
Cemiplimab, Prednisone, Sirolimus, Cetuximab (EGFR inhibitor)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

NCT06060587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 7, 2026, 6:26 PM EDT
Active, not recruiting Phase 1 Interventional

Safe Accelerated Venetoclax Escalation in CLL

NCT04843904
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Venetoclax, Obinutuzumab, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 7, 2026, 6:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

NCT04793750
View directory record Official record
Conditions
HIV Infections, Syphilis
Interventions
Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 7, 2026, 6:26 PM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 7, 2026, 6:26 PM EDT
Terminated Phase 2 Interventional

AT1001 for the Treatment of COVID-19 Related MIS-C

NCT05022303
View directory record Official record
Conditions
Covid19, Multisystem Inflammatory Syndrome in Children
Interventions
Larazotide Acetate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 7, 2026, 6:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

NCT00746941
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
mefloquine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 7, 2026, 6:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care

NCT00787839
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Prediabetic State
Interventions
Glucose challenge test, Glucose tolerance test
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2015 · Synced Sep 7, 2026, 6:26 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Oral Intake During Labor

NCT03276741
View directory record Official record
Conditions
Labor Complication, Food Aspiration, Complication of Anesthesia, Satisfaction
Interventions
gastric soft/bland diet
Dietary Supplement
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 7, 2026, 6:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 7, 2026, 6:26 PM EDT
Recruiting No phase listed Observational

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

NCT06744296
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Blood Draws and Tissue Sample(s)
Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 7, 2026, 6:26 PM EDT
Withdrawn Phase 2 Interventional

Acetazolamide for the Prevention of Post Operative CSF Leak

NCT04351061
View directory record Official record
Conditions
Cerebrospinal Fluid Leak
Interventions
Acetazolamide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 7, 2026, 6:26 PM EDT
Completed Not applicable Interventional Results available

Dexcom Continuous Glucose Monitoring in Long-term Care

NCT04818242
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Dexcom G6 CGM with GTS, POC Blood Glucose Test + Blinded CGM
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 7, 2026, 6:26 PM EDT